Compare Adaptive Biotechnologies Corp (ADPT) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Ferrari NV — how do they compare? Adaptive Biotechnologies Corp trades at $25.11 (market cap $4.04B), while Ferrari NV trades at $406.57 (market cap $71.67B). The key difference: Ferrari NV is far larger — about 17.7× Adaptive Biotechnologies Corp's market cap, and Ferrari NV pays a 1.04% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | RACE | |
|---|---|---|
Market Cap | $4.04B | $71.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $504.09 |
52-Week Low | $12.30 | $314.63 |
Enterprise Value | $4.10B | $73.60B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Ferrari (RACE) trades at $407.76, up 0.24% today, near its pivot point of $407 with bullish technical indicators. The stock shows strong fundamentals with a 22.25% net margin and consistent earnings beats, including Q2 2026 EPS of $2.99 versus $2.83 expected. Revenue growth is steady, reaching $7.15B in 2025, supported by high demand and personalization revenue.
Outlook remains positive with a consensus price target of $462.67, though elevated P/E of 37.93 poses valuation risk. Key opportunities include pricing power and EV expansion, while risks involve economic sensitivity and execution on new models. Analyst sentiment is strongly bullish with 72% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
